610 related articles for article (PubMed ID: 16420202)
1. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
2. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
4. Physical function in men with prostate cancer on androgen deprivation therapy.
Clay CA; Perera S; Wagner JM; Miller ME; Nelson JB; Greenspan SL
Phys Ther; 2007 Oct; 87(10):1325-33. PubMed ID: 17684084
[TBL] [Abstract][Full Text] [Related]
5. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
6. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
7. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
8. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
[TBL] [Abstract][Full Text] [Related]
9. Long-term impact of androgen-deprivation therapy on physical function and quality of life.
Alibhai SM; Breunis H; Timilshina N; Naglie G; Tannock I; Krahn M; Warde P; Fleshner NE; Canning SD; Tomlinson G
Cancer; 2015 Jul; 121(14):2350-7. PubMed ID: 25809861
[TBL] [Abstract][Full Text] [Related]
10. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
11. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
12. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
[TBL] [Abstract][Full Text] [Related]
13. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Lubeck DP; Grossfeld GD; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
[TBL] [Abstract][Full Text] [Related]
14. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer.
Kato T; Komiya A; Suzuki H; Imamoto T; Ueda T; Ichikawa T
Int J Urol; 2007 May; 14(5):416-21. PubMed ID: 17511724
[TBL] [Abstract][Full Text] [Related]
15. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
[TBL] [Abstract][Full Text] [Related]
16. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
Lee CE; Leslie WD; Lau YK
BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
20. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy.
Chipperfield K; Fletcher J; Millar J; Brooker J; Smith R; Frydenberg M; Burney S
Psychooncology; 2013 Oct; 22(10):2169-76. PubMed ID: 23483679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]